Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.

Antimicrobial agents and chemotherapy - 1 Jan 2010

Liverton Nigel J, Carroll Steven S, Dimuzio Jillian, Fandozzi Christine, Graham Donald J, Hazuda Daria, Holloway M Katherine, Ludmerer Steven W, McCauley John A, McIntyre Charles J, Olsen David B, Rudd Michael T, Stahlhut Mark, Vacca Joseph P

Abstract excerpt

The administration of hepatitis C virus (HCV) NS3/4A protease inhibitors to patients with chronic HCV infections has demonstrated that they have dramatic antiviral effects and that compounds acting via this mechanism are likely to form a key component of future anti-HCV therapy. We report here on the preclinical profile of MK-7009, an inhibitor of genotype 1a and 1b proteases at subnanomolar concentrations with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclopropanes
Share to Half-Life

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Lactams, Macrocyclic

Share to Macaca mulatta

Share to Pan troglodytes

Share to Protease Inhibitors

Share to Replicon

Source

Open in PubMed Open full text

Identifiers

PMID: 19841155
DOI: 10.1128/AAC.00677-09
PMCID: PMC2798506

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.PMID 19841155Read ↗

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.Semantic proximity Read ↗

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).Semantic proximity Read ↗

Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.Semantic proximity Read ↗

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.Semantic proximity Read ↗

Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Bio-Logical and Pharmacological ProfilingSemantic proximity Read ↗

Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Semantic proximity Read ↗

The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.Semantic proximity Read ↗

Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.Semantic proximity Read ↗

Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.Semantic proximity Read ↗

Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.Semantic proximity Read ↗

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.